{
    "nct_id": "NCT04522180",
    "official_title": "An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly",
    "inclusion_criteria": "1. Males or females with a documented diagnosis of Acromegaly* who are 18 to 75 years old (inclusive) at the time of informed consent.\n2. Have had pituitary surgery (e.g. transsphenoidal) unless there was a contraindication to surgery and are either acromegaly medical treatment naïve, or who had not taken any other acromegaly medications prior to the screening visit as outlined below\n\n   * bromocriptine: 2 weeks\n   * cabergoline: 4 weeks\n   * quinagolide: 4 weeks\n   * octreotide daily injection (SC) or oral formulation: 4 weeks\n   * pegvisomant: 4 weeks\n   * octreotide LAR: 3 months\n   * pasireotide LAR: 4 months\n   * lanreotide (all formulations): 3 months\n3. At Screening, serum IGF-1 (performed at the central lab) between 1.3 to 5 × ULN, inclusive, adjusted for age and sex.\n4. Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, abstinent, or using 1 highly effective method of birth control\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Participants who received surgery for pituitary adenoma within the last 3 months before the trial, and/or planning to receive surgery during the trial\n2. Participants who received radiotherapy for pituitary adenoma within the last 2 years before the trial, and/or planning to receive radiotherapy during the trial\n3. Participants with a pituitary tumor that, per Investigator judgment, is worsening (e.g., either growing or at risk of compressing or abutting the optic chiasm or other vital structures) as assessed by pituitary/sellar MRI protocol at Screening or within 3 months of Screening. CT scan is allowed if MRI is contraindicated\n4. Evidence of decompensated cardiac function per medical judgement and/or New York Heart Association (NYHA) Class 3 or 4\n5. Clinical evidence of symptomatic hyperprolactinemia that would necessitate treatment\n6. Symptomatic cholelithiasis, and/or choledocholithiasis",
    "miscellaneous_criteria": ""
}